{"id":"oral-polio-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Vaccine-derived poliovirus (VDPV) shedding"},{"rate":"rare, <1 per million doses","effect":"Vaccine-associated paralytic poliomyelitis (VAPP) in immunocompromised individuals"},{"rate":null,"effect":"Mild gastrointestinal symptoms"}]},"_chembl":{"chemblId":"CHEMBL2108778","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"OPV contains three serotypes of live attenuated poliovirus that replicate in the intestinal tract, triggering both mucosal (IgA) and systemic (IgG) immune responses. This oral administration induces intestinal immunity and prevents poliovirus replication and shedding, providing protection against all three poliovirus types and contributing to herd immunity through vaccine virus shedding.","oneSentence":"Oral Polio Vaccine stimulates the immune system to produce antibodies against poliovirus by delivering live attenuated (weakened) poliovirus strains orally.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:58:44.907Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of poliomyelitis caused by poliovirus types 1, 2, and 3"},{"name":"Routine childhood immunization against polio"}]},"trialDetails":[{"nctId":"NCT05794230","phase":"PHASE3","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-03-27","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":1528},{"nctId":"NCT06895486","phase":"PHASE2","title":"Study of Co-administered (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Evaluation","status":"RECRUITING","sponsor":"PATH","startDate":"2025-11-11","conditions":"Poliomyelitis","enrollment":675},{"nctId":"NCT05644184","phase":"PHASE2","title":"Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh","status":"RECRUITING","sponsor":"PATH","startDate":"2023-03-27","conditions":"Poliomyelitis","enrollment":2232},{"nctId":"NCT06331156","phase":"PHASE3","title":"A Study on the Immune Response and Safety of Inactivated Poliovirus Vaccine (IPV) When Co-administered With Human Rotavirus (HRV) Porcine Circovirus (PCV)-Free Vaccine in Healthy Chinese Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-03-22","conditions":"Gastroenteritis","enrollment":400},{"nctId":"NCT04429295","phase":"PHASE3","title":"Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-06-28","conditions":"Pertussis Immunisation, Diphtheria Immunisation, Polio Immunisation","enrollment":460},{"nctId":"NCT05155579","phase":"PHASE1","title":"Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2022-05-14","conditions":"Malaria","enrollment":593},{"nctId":"NCT06879327","phase":"PHASE2","title":"Infant Malaria Vaccine Schedule Optimization","status":"RECRUITING","sponsor":"PATH","startDate":"2025-05-30","conditions":"Malaria Vaccines","enrollment":1200},{"nctId":"NCT05621876","phase":"","title":"Evaluation of an IgG Deficiency Rapid Screening Test: A Performance Study With Primary Immunodeficiency (PID) Patients in Tunisia","status":"COMPLETED","sponsor":"PATH","startDate":"2024-05-15","conditions":"Primary Immunodeficiency Diseases","enrollment":50},{"nctId":"NCT06137664","phase":"PHASE1, PHASE2","title":"Study of Trivalent and Bivalent (Types 1 & 2) Novel Oral Poliomyelitis Vaccines","status":"RECRUITING","sponsor":"PATH","startDate":"2024-11-20","conditions":"Poliomyelitis","enrollment":2400},{"nctId":"NCT01375647","phase":"PHASE3","title":"Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in Bangladesh","status":"COMPLETED","sponsor":"University of Vermont","startDate":"2011-05","conditions":"Rotavirus Diarrhea, Vaccine Virus Shedding, Tropical Enteropathy","enrollment":700},{"nctId":"NCT06218368","phase":"NA","title":"A Tool Kit to Improve Vaccine Confidence in the Philippines","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Toronto","startDate":"2024-01-31","conditions":"Measles, Polio, Vaccination Hesitancy","enrollment":5400},{"nctId":"NCT06748612","phase":"PHASE4","title":"Immunogenicity of Different Primary Immunization Schedules with Inactivated Poliovirus Vaccine (IPV) Plus Pentavalent Vaccine (DTwP-HBV-Hib) or with Hexavalent Vaccine (DTwP-HBV-Hib-IPV)","status":"NOT_YET_RECRUITING","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2025-01-28","conditions":"Polio","enrollment":1190},{"nctId":"NCT04529538","phase":"PHASE1","title":"Study of Novel Types 1 and 3 Oral Poliomyelitis Vaccines","status":"COMPLETED","sponsor":"PATH","startDate":"2021-03-26","conditions":"Poliomyelitis","enrollment":226},{"nctId":"NCT04579510","phase":"PHASE2","title":"Immunogenicity nOPV2 With and Without bOPV","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2021-02-08","conditions":"Poliomyelitis","enrollment":795},{"nctId":"NCT03460002","phase":"PHASE4","title":"Vaccine Campaign Effects on General Hospital Admissions and Mortality Among Children","status":"COMPLETED","sponsor":"Bandim Health Project","startDate":"2016-11","conditions":"Measles Vaccination, Oral Polio Vaccine, Non-specific/Heterologous Effects of Vaccines","enrollment":28612},{"nctId":"NCT05033561","phase":"PHASE3","title":"Study to Evaluate Safety and Immunogenicity of nOPV2 at Different Intervals in Infants","status":"COMPLETED","sponsor":"Fidec Corporation","startDate":"2021-12-16","conditions":"Poliomyelitis","enrollment":905},{"nctId":"NCT02961595","phase":"PHASE1","title":"Live Enterovirus Vaccine and Type 1 Diabetes","status":"COMPLETED","sponsor":"Tampere University","startDate":"1999-10","conditions":"Enterovirus Infection, Type 1 Diabetes, Prediabetic State","enrollment":315},{"nctId":"NCT04481191","phase":"PHASE3","title":"Immunogenicity and Safety of Concomitant and Non-Concomitant Administration of RotaTeq® (V260) and Inactivated Poliomyelitis Vaccine in Healthy Chinese Infants (V260-074)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-08-25","conditions":"Prevention of Rotavirus Gastroenteritis in Infants and Children Caused by Serotypes G1, G2, G3, G4, and G9","enrollment":400},{"nctId":"NCT05654467","phase":"PHASE2","title":"Study of a Novel Type 3 Oral Poliomyelitis Vaccine in Panama","status":"UNKNOWN","sponsor":"PATH","startDate":"2023-12-05","conditions":"Poliomyelitis","enrollment":1532},{"nctId":"NCT06266754","phase":"PHASE4","title":"The Non-Specific Immunological Effects of Providing Oral Polio Vaccine to Seniors in Guinea-Bissau","status":"UNKNOWN","sponsor":"Bandim Health Project","startDate":"2024-01-29","conditions":"Vaccine Reaction","enrollment":80},{"nctId":"NCT03564782","phase":"EARLY_PHASE1","title":"Examining Bioactivity of PVSRIPO in Invasive Breast Cancer","status":"COMPLETED","sponsor":"Istari Oncology, Inc.","startDate":"2019-06-30","conditions":"Invasive Breast Cancer","enrollment":5},{"nctId":"NCT05397678","phase":"PHASE4","title":"Trial to Compare BCG-Bulgaria and BCG-Denmark","status":"UNKNOWN","sponsor":"Bandim Health Project","startDate":"2022-10-21","conditions":"Death; Neonatal, Death, Infant, Morbidity;Newborn","enrollment":15000},{"nctId":"NCT04383925","phase":"PHASE4","title":"Trial to Compare Two Strains of BCG","status":"COMPLETED","sponsor":"Bandim Health Project","startDate":"2020-05-04","conditions":"Death, Infant, Morbidity;Infant","enrollment":16390},{"nctId":"NCT03554798","phase":"PHASE2","title":"A Study to Evaluate the Safety and Immunogenicity of Novel Oral Polio Vaccine","status":"COMPLETED","sponsor":"Fidec Corporation","startDate":"2018-12-04","conditions":"Poliomyelitis","enrollment":1025},{"nctId":"NCT05327426","phase":"PHASE1","title":"Intradermal Fractional Dose IPV (fIPV) in Combination With dmLT","status":"UNKNOWN","sponsor":"University of Vermont","startDate":"2022-04-01","conditions":"Poliomyelitis","enrollment":19},{"nctId":"NCT06114810","phase":"PHASE4","title":"Immunogenicity of Novel Oral Poliovirus Vaccine Type 2 (nOPV2), bOPV and IPV","status":"UNKNOWN","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2023-11","conditions":"Polio","enrollment":880},{"nctId":"NCT03632720","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-10","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":788},{"nctId":"NCT03630705","phase":"PHASE3","title":"Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":525},{"nctId":"NCT03614702","phase":"PHASE3","title":"Clinic Trial to Evaluate the Safety and Immunogenicity by Different Sequential Schedules of bOPV and IPV","status":"COMPLETED","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2015-09-15","conditions":"Poliomyelitis","enrollment":1200},{"nctId":"NCT02231632","phase":"PHASE2, PHASE3","title":"The Immunogenicity and Safety of Live Attenuated Poliomyelitis Vaccine (Human Diploid Cell)","status":"COMPLETED","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2011-01","conditions":"Poliomyelitis","enrollment":1200},{"nctId":"NCT01491893","phase":"PHASE1","title":"PVSRIPO for Recurrent Glioblastoma (GBM)","status":"COMPLETED","sponsor":"Istari Oncology, Inc.","startDate":"2012-04-25","conditions":"GBM, Glioblastoma, Glioma","enrollment":61},{"nctId":"NCT02580201","phase":"PHASE4","title":"A Study to Evaluate Safety and Immunogenicity of tOPV in 1 to 5 Years and at 6 Weeks of Age","status":"COMPLETED","sponsor":"Fidec Corporation","startDate":"2015-11","conditions":"Poliomyelitis","enrollment":154},{"nctId":"NCT05083039","phase":"","title":"Observational Program, Study the Preventive Efficacy of the BiVac Polio Vaccine Against the Incidence of Acute Respiratory Infections, Including COVID-19","status":"COMPLETED","sponsor":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products","startDate":"2020-05-14","conditions":"Coronavirus Infections, Vaccine, Polio","enrollment":1500},{"nctId":"NCT04232943","phase":"PHASE1","title":"Inactivated Poliovirus Vaccine (IPV) With or Without E.Coli Double Mutant Heat-Labile Toxin (dmLT) Challenge Study in Healthy Adults","status":"COMPLETED","sponsor":"PATH","startDate":"2020-01-22","conditions":"Polio","enrollment":87},{"nctId":"NCT04693286","phase":"PHASE2","title":"Clinical Trial of Novel OPV2 Vaccine","status":"COMPLETED","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2020-09-21","conditions":"Poliomyelitis","enrollment":330},{"nctId":"NCT04893616","phase":"NA","title":"Cameroon HepB Birth Dose Feasibility Pilot","status":"COMPLETED","sponsor":"Clinton Health Access Initiative Inc.","startDate":"2021-06-10","conditions":"Hepatitis B","enrollment":13},{"nctId":"NCT03581734","phase":"PHASE3","title":"Immunogenicity of Co-administered Oral Polio Vaccine and Oral Cholera Vaccine","status":"UNKNOWN","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2018-07-01","conditions":"Vaccine Reaction","enrollment":579},{"nctId":"NCT04445428","phase":"PHASE4","title":"OPV as Potential Protection Against COVID-19","status":"UNKNOWN","sponsor":"Bandim Health Project","startDate":"2020-07-15","conditions":"Poliovirus Vaccine, Oral, COVID, Mortality","enrollment":3400},{"nctId":"NCT02504203","phase":"PHASE4","title":"Can Earlier BCG Vaccination Reduce Early Infant Mortality? A Randomised Trial","status":"TERMINATED","sponsor":"Bandim Health Project","startDate":"2015-11","conditions":"Infant Mortality, BCG","enrollment":2332},{"nctId":"NCT05166031","phase":"PHASE3","title":"Evaluation of the Immunogenicity and Safety of Concomitant Administration of Novel Oral Polio Type 2 Vaccine and Bivalent Oral Polio Vaccine","status":"WITHDRAWN","sponsor":"Fidec Corporation","startDate":"2020-12","conditions":"Poliomyelitis","enrollment":""},{"nctId":"NCT04544787","phase":"PHASE2","title":"A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates","status":"COMPLETED","sponsor":"Pierre Van Damme","startDate":"2018-10-22","conditions":"Poliomyelitis","enrollment":250},{"nctId":"NCT04870021","phase":"PHASE4","title":"Hepatitis B Birth Dose for Newborns","status":"COMPLETED","sponsor":"Quaid-e-Azam University","startDate":"2015-03-15","conditions":"Hepatitis B, Immunization; Infection","enrollment":218},{"nctId":"NCT00625482","phase":"NA","title":"Sex-Differential Health Interventions In Low-Birth-Weight Infants","status":"COMPLETED","sponsor":"Bandim Health Project","startDate":"2008-02","conditions":"Mortality, Morbidity, Growth","enrollment":""},{"nctId":"NCT03722004","phase":"PHASE4","title":"Monovalent Oral Poliovirus Vaccine Type 1 Intestinal and Humoral Immunity Study","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2018-12-18","conditions":"Poliomyelitis","enrollment":1256},{"nctId":"NCT01908114","phase":"PHASE4","title":"To Develop, Implement and Evaluate the Polio Demonstration Project Comprising of a Community Based Intervention Package for Polio Eradication in Pakistan","status":"UNKNOWN","sponsor":"Aga Khan University","startDate":"2013-07","conditions":"Polio, Polio Sero Conversion, Polio Sero Prevalence","enrollment":60000},{"nctId":"NCT01229579","phase":"NA","title":"Effect of Zinc Supplementation on Response to Oral Polio Vaccine in Infants in Pakistan","status":"COMPLETED","sponsor":"Aga Khan University","startDate":"2010-05","conditions":"Poliomyelitis","enrollment":320},{"nctId":"NCT03430349","phase":"PHASE1","title":"Phase 1 Novel Live Attenuated Serotype 2 Oral Polio Vaccine Study in Inactivated Polio Vaccine (IPV) Primed Adults","status":"COMPLETED","sponsor":"Pierre Van Damme","startDate":"2017-05-16","conditions":"Poliomyelitis","enrollment":30},{"nctId":"NCT02447536","phase":"PHASE4","title":"Trial of Two Strains of BCG","status":"COMPLETED","sponsor":"Bandim Health Project","startDate":"2014-12-08","conditions":"Morbidity, Bacille Calmette-Guérin","enrollment":12006},{"nctId":"NCT03202719","phase":"PHASE4","title":"Duration of IPV Priming and Antibody Decay","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2017-11-05","conditions":"Poliomyelitis","enrollment":1645},{"nctId":"NCT00263666","phase":"PHASE2","title":"A Study of Safety, Reactogenicity and Immunogenicity of HRV Vaccine in HIV Infected Infants in South Africa","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-03-16","conditions":"Infections, Rotavirus","enrollment":100},{"nctId":"NCT04540185","phase":"PHASE3","title":"A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19","status":"UNKNOWN","sponsor":"Biomed Industries, Inc.","startDate":"2020-11-01","conditions":"Covid19, SARS (Severe Acute Respiratory Syndrome), SARS-CoV Infection","enrollment":3600},{"nctId":"NCT02521974","phase":"PHASE4","title":"A Study to Evaluate the Safety and Immunogenicity of Oral Polio Vaccine Type 2 in Infants and Children","status":"COMPLETED","sponsor":"Fidec Corporation","startDate":"2015-10","conditions":"Adverse Event Following Immunisation","enrollment":164},{"nctId":"NCT04504539","phase":"NA","title":"Use of mOPV1 in Routine Immunization in Pakistan.","status":"UNKNOWN","sponsor":"Aga Khan University","startDate":"2020-08","conditions":"Oral Polio Vaccine","enrollment":560},{"nctId":"NCT02434770","phase":"PHASE3","title":"Immunogenicity and Safety of Liquid Bivalent Oral Poliomyelitis Vaccine","status":"COMPLETED","sponsor":"PATH","startDate":"2015-08","conditions":"Poliomyelitis","enrollment":750},{"nctId":"NCT01021293","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Poliorix™ Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-11-28","conditions":"Poliomyelitis, Poliomyelitis Vaccines","enrollment":1101},{"nctId":"NCT02582255","phase":"PHASE4","title":"A Study to Evaluate the Safety and Immunogenicity of Monovalent OPV2 in Children Aged 1 to 5 Years in Lithuania","status":"COMPLETED","sponsor":"Fidec Corporation","startDate":"2015-11","conditions":"Poliomyelitis","enrollment":100},{"nctId":"NCT02207816","phase":"PHASE3","title":"An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-18","conditions":"Malaria","enrollment":3084},{"nctId":"NCT00678301","phase":"PHASE3","title":"Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A, Zilbrix™ Hib and Polio Sabin™","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-06-18","conditions":"Infections, Streptococcal","enrollment":365},{"nctId":"NCT02408926","phase":"PHASE4","title":"Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in Thailand","status":"COMPLETED","sponsor":"Universiteit Antwerpen","startDate":"2015-04","conditions":"Pertussis","enrollment":370},{"nctId":"NCT00866619","phase":"PHASE3","title":"Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-03-27","conditions":"Malaria","enrollment":15459},{"nctId":"NCT02766816","phase":"PHASE3","title":"A Clinical Study Comparing Safety and Immunogenicity of bOPV of Bilthoven Biologicals","status":"COMPLETED","sponsor":"Bilthoven Biologicals","startDate":"2016-06-08","conditions":"Immune Response to Oral Polio Vaccine","enrollment":1120},{"nctId":"NCT01345240","phase":"PHASE3","title":"Study to Evaluate Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-11-17","conditions":"Malaria, Malaria Vaccines","enrollment":705},{"nctId":"NCT01098474","phase":"PHASE2","title":"Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-07","conditions":"Tuberculosis","enrollment":301},{"nctId":"NCT01262872","phase":"PHASE2","title":"Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-02-09","conditions":"Infections, Streptococcal","enrollment":1320},{"nctId":"NCT01175083","phase":"PHASE3","title":"Immunization of Children Between 8 Weeks and 2 Years of Age With GSK Pneumococcal Vaccine GSK1024850A","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-06-01","conditions":"Infections, Streptococcal","enrollment":300},{"nctId":"NCT01341639","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2011-05-26","conditions":"Bacterial Infections, Virus Diseases","enrollment":1250},{"nctId":"NCT01480258","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2011-11-23","conditions":"Bacterial Infections, Virus Diseases","enrollment":1315},{"nctId":"NCT01839188","phase":"PHASE3","title":"Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2013-05-01","conditions":"Neisseria Meningitidis, Bacterial Infections, Virus Diseases","enrollment":385},{"nctId":"NCT03822767","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a \"2+1\"Sequential Schedule With bOPV in Infants","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2018-06-12","conditions":"Poliomyelitis","enrollment":240},{"nctId":"NCT03822754","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a '1+2' Sequential Schedule With bOPV in Infants","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2018-06-06","conditions":"Poliomyelitis","enrollment":240},{"nctId":"NCT03821441","phase":"PHASE3","title":"Trail To Evaluate the Immune Effects of Primary and Booster Immunizations With Poliovirus Vaccine","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2018-01-04","conditions":"Poliomyelitis","enrollment":1165},{"nctId":"NCT02710045","phase":"NA","title":"The Interaction Between Measles and DTP Vaccination","status":"COMPLETED","sponsor":"Medical Research Council Unit, The Gambia","startDate":"2007-11","conditions":"Non-target Heterologous Effects of Vaccines, Vaccine Interactions","enrollment":302},{"nctId":"NCT00547248","phase":"PHASE3","title":"Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-10-22","conditions":"Infections, Streptococcal","enrollment":756},{"nctId":"NCT01616693","phase":"PHASE4","title":"Zinc and/or Probiotic Supplementation of Rotavirus and Oral Polio Virus Vaccines","status":"COMPLETED","sponsor":"PATH","startDate":"2012-07","conditions":"Immunity to Oral Rotavirus Vaccine, Immunity to Oral Polio Vaccine, Shedding of Oral Rotavirus Vaccine","enrollment":620},{"nctId":"NCT00344318","phase":"PHASE3","title":"Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-08-07","conditions":"Infections, Streptococcal","enrollment":806},{"nctId":"NCT02062385","phase":"PHASE3","title":"Efficacy, Safety, and Immunogenicity of V260 in Healthy Chinese Infants (V260-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-05-30","conditions":"Rotavirus Gastroenteritis","enrollment":4040},{"nctId":"NCT01340937","phase":"PHASE3","title":"A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-05-10","conditions":"Bacterial Infections, Virus Diseases","enrollment":2808},{"nctId":"NCT01337167","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-04-19","conditions":"Bacterial Infections, Virus Diseases","enrollment":1473},{"nctId":"NCT01926015","phase":"PHASE4","title":"Immunogenicity and Safety of Concomitant Administration of RotaTeq™ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-09-19","conditions":"Rotavirus Disease","enrollment":192},{"nctId":"NCT00829010","phase":"PHASE3","title":"Primary and Booster Vaccination Study With a Pneumococcal Vaccine in HIV Infected, HIV Exposed Uninfected and HIV Uninfected Children 6 to 10 Weeks of Age.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-02-17","conditions":"Infections, Streptococcal","enrollment":489},{"nctId":"NCT00436007","phase":"PHASE2","title":"Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04-30","conditions":"Malaria","enrollment":511},{"nctId":"NCT01231503","phase":"PHASE2","title":"Safety and Immunogenicity of GSK Biologicals' Malaria Vaccine 257049 When Administered on 7 Schedules to African Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-01-13","conditions":"Malaria","enrollment":480},{"nctId":"NCT01171963","phase":"PHASE3","title":"Study to Assess the Efficacy, Immunogenicity and Safety of Liquid Human Rotavirus Vaccine, in Healthy Chinese Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-08-29","conditions":"Infections, Rotavirus","enrollment":3340},{"nctId":"NCT02643368","phase":"PHASE4","title":"Immunogenicity of Monovalent Type 2 Oral Poliovirus Vaccine","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2015-12","conditions":"Poliomyelitis","enrollment":760},{"nctId":"NCT03310073","phase":"PHASE4","title":"Immunogenicity and Safety Profile of Primary Dose of bOPV Bio Farma Given Simultaneously With Pentabio And IPV","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2016-07","conditions":"Healthy","enrollment":143},{"nctId":"NCT01839175","phase":"PHASE3","title":"Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2013-04","conditions":"Neisseria Meningitidis, Bacterial Infections, Virus Diseases","enrollment":350},{"nctId":"NCT01571505","phase":"PHASE1","title":"Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in INDIA (PROVIDE)","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2012-03-01","conditions":"Poliomyelitis, Tropical Enteropathy","enrollment":372},{"nctId":"NCT02643446","phase":"","title":"Serological Survey on Monitoring the Positive Rate After Vaccination of Inactivated Polio Vaccine","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention, China","startDate":"2015-08","conditions":"Poliomyelitis","enrollment":809},{"nctId":"NCT01457560","phase":"PHASE3","title":"Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib Vaccine Followed by the Same Vaccine and Oral Polio Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2000-02","conditions":"Hepatitis B, Acellular Pertussis, Haemophilus Influenzae Type b","enrollment":80},{"nctId":"NCT01056705","phase":"PHASE2","title":"The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains (IPV)","status":"COMPLETED","sponsor":"Chinese Academy of Medical Sciences","startDate":"2009-07","conditions":"Poliomyelitis","enrollment":500},{"nctId":"NCT00514709","phase":"PHASE3","title":"Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB PRP~T Combined Vaccine in Filipino Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-09","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":1843},{"nctId":"NCT02412514","phase":"PHASE4","title":"Intestinal and Humoral Immunity of Sequential Polio Vaccination Schedules","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2015-04","conditions":"Poliomyelitis","enrollment":456},{"nctId":"NCT02785705","phase":"PHASE3","title":"Randomized Controlled Trial for Immunogenicity and Safety Evaluation of Bivalent Types 1 and 3 Oral Poliovirus Vaccine","status":"COMPLETED","sponsor":"Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control","startDate":"2015-04","conditions":"Poliomyelitis","enrollment":600},{"nctId":"NCT01559636","phase":"NA","title":"Diarrhea and Bivalent Oral Polio Vaccine Immunity","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2012-08","conditions":"Seroimmunity, Diarrhea, Polio","enrollment":699},{"nctId":"NCT02291263","phase":"PHASE3","title":"Immunogenicity of Intramuscular Inactivated Poliovirus Vaccine","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2014-10","conditions":"Poliomyelitis","enrollment":738},{"nctId":"NCT01831050","phase":"PHASE4","title":"Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine","status":"COMPLETED","sponsor":"Fidec Corporation","startDate":"2013-05","conditions":"Poliomyelitis","enrollment":1420},{"nctId":"NCT02111135","phase":"PHASE2","title":"Safety Study of a Single Dose of Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine (m-IPV2 HD) in Infants Early in Life","status":"COMPLETED","sponsor":"Vaxtrials S.A.","startDate":"2014-04","conditions":"Polio","enrollment":240},{"nctId":"NCT01586572","phase":"NA","title":"Pakistan Short Interval mOPV1 Compared With Standard Interval mOPV1 and bOPV 1,3","status":"COMPLETED","sponsor":"Aga Khan University","startDate":"2012-04","conditions":"Polio","enrollment":1000},{"nctId":"NCT00130832","phase":"PHASE3","title":"Concomitant Use and Staggered Use of Vaccine and Oral Poliovirus (OPV) in Healthy Infants (V260-014)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-10","conditions":"Rotavirus Infections, Gastroenteritis","enrollment":735},{"nctId":"NCT01475539","phase":"PHASE4","title":"Sequential Inactivated Poliomyelitis Vaccine Followed by Oral Poliomyelitis Vaccine Versus Oral Poliomyelitis Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-11","conditions":"Polio, Poliomyelitis","enrollment":456}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1179,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Biopolio®"],"phase":"marketed","status":"active","brandName":"Oral Polio Vaccine","genericName":"Oral Polio Vaccine","companyName":"International Centre for Diarrhoeal Disease Research, Bangladesh","companyId":"international-centre-for-diarrhoeal-disease-research-bangladesh","modality":"Biologic","firstApprovalDate":"","aiSummary":"Oral Polio Vaccine stimulates the immune system to produce antibodies against poliovirus by delivering live attenuated (weakened) poliovirus strains orally. Used for Poliomyelitis prevention in infants and children, Polio outbreak response and eradication campaigns.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}